Using a Nonparametric Multilevel Latent Markov Model to Evaluate Diagnostics for Trachoma

American Journal of Epidemiology

Volumn 177, Issue 9, 2013, Pages 913-922

  Koukounari, Artemis ^a   Moustaki, Irini ^b   Grassly, Nicholas C ^a   Blake, Isobel M ^a   Basáñez, María Gloria ^a   Gambhir, Manoj ^a   Mabey, David C W ^c   Bailey, Robin L ^c   Burton, Matthew J ^c   Solomon, Anthony W ^c   Donnelly, Christl A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

diagnosis; latent Markov model; multilevel; nonparametric model; trachoma

Indexed keywords

AZITHROMYCIN;

ACCURACY ASSESSMENT; COHORT ANALYSIS; DISEASE CONTROL; DISEASE INCIDENCE; EPIDEMIOLOGY; ESTIMATION METHOD; MARKOV CHAIN; NUMERICAL MODEL; OPTIMIZATION; PARAMETERIZATION; PROBABILITY; WASTE MANAGEMENT;

ARTICLE; CHLAMYDIASIS; CLINICAL EVALUATION; COHORT ANALYSIS; DIAGNOSTIC TEST; GAMBIA; GOLD STANDARD; HUMAN; INFLAMMATION; LONGITUDINAL STUDY; NONPARAMETRIC MULTILEVEL LATENT MARKOV MODEL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROBABILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TANZANIA; TRACHOMA;

DIAGNOSIS; LATENT MARKOV MODEL; MULTILEVEL; NONPARAMETRIC MODEL; TRACHOMA;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHLAMYDIA TRACHOMATIS; DISEASE ERADICATION; ENDEMIC DISEASES; GAMBIA; HUMANS; LONGITUDINAL STUDIES; MARKOV CHAINS; MODELS, BIOLOGICAL; POPULATION SURVEILLANCE; PREVALENCE; STATISTICS, NONPARAMETRIC; TANZANIA; TRACHOMA;

GAMBIA; TANZANIA;

CHLAMYDIA TRACHOMATIS;

EID: 84877245791     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws345     Document Type: Article

References (43)

1. Banoo S, Bell D, Bossuyt P, et al. Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol. 2010;8(12 suppl):17S-29S.
2. Mariotti SP, Pascolini D, Rose-Nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol. 2009;93(5):563-568.
3. World Health Organization, London School of Hygiene and Tropical Medicine, International Trachoma Inititative. Trachoma: A Guide for Programme Managers. Geneva, Switzerland: World Health Organization; 2006.
4. Miller K, Schmidt G, Melese M, et al. How reliable is the clinical exam in detecting ocular chlamydial infection? Ophthalmic Epidemiol. 2004;11(3):255-262.
5. Solomon AW, Peeling RW, Foster A, et al. Diagnosis and assessment of trachoma. Clin Microbiol Rev. 2004;17(4): 982-1011.
6. Taylor HR, Rapoza PA, West S, et al. The epidemiology of infection in trachoma. Invest Ophthalmol Vis Sci. 1989; 30(8):1823-1833.
7. Bailey RL, Hampton TJ, Hayes LJ, et al. Polymerase chain reaction for the detection of ocular chlamydial infection in trachoma-endemic communities. J Infect Dis. 1994;170(3): 709-712.
8. Bailey RL, Arullendran P, Whittle HC, et al. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet. 1993;342(8869):453-456.
9. Burton MJ, Hu VH, Massae P, et al. What is causing active trachoma? The role of nonchlamydial bacterial pathogens in a low prevalence setting. Invest Ophthalmol Vis Sci. 2011; 52(8):6012-6017.
10. See CW, Alemayehu W, Melese M, et al. How reliable are tests for trachoma? A latent class approach. Invest Ophthalmol Vis Sci. 2011;52(9):6133-6137.
11. Rabe-Hesketh S, Skrondal A. Classical latent variable models for medical research. Stat Methods Med Res. 2008;17(1):5-32.
12. Yang I, Becker MP. Latent variable modeling of diagnostic accuracy. Biometrics. 1997;53(3):948-958.
13. Grassly NC, Ward ME, Ferris S, et al. The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up. PLoS Negl Trop Dis. 2008;2(12):e341.
14. Chen HH, Duffy SW, Tabar L. A Markov chain method to estimate the tumour progression rate from preclinical to clinical phase, sensitivity and positive predicitive value for mammography in breast cancer screeining. J R Stat Soc SerD (The Statistician). 1996;45(3):307-317.
15. Guihenneuc-Jouyaux C, Richardson S, Longini IM Jr. Modeling markers of disease progression by a hidden Markov process: application to characterizing CD4 cell decline. Biometrics. 2000;56(3):733-741.
16. Jackson CH, Sharples LD. Hidden Markov models for the onset and progression of bronchiolitis obliterans syndrome in lung transplant recipients. Stat Med. 2002;21(1):113-128.
17. Jackson CH, Sharples LD, Thompson SG, et al. Multistate Markov models for disease progression with classification error. J R Stat Soc Ser D (The Statistician). 2003;52(2): 193-209.
18. Satten GA, Longini IM Jr. Markov chains with measurement error: estimating the 'true' course of a marker of the progression of human immunodeficiency virus disease. Appl Stat. 1996;45(3):275-309.
19. Keenan JD, See CW, Moncada J, et al. Diagnostic test characteristics of tests for ocular Chlamydia after mass azithromycin distributions. Invest Ophthalmol Vis Sci. 2012; 53(1):235-240.
20. Bartholomew D, Knott M, Moustaki I, eds. Latent Variable Models and Factor Analysis: A Unified Approach. London, United Kingdom: John Wiley and Sons; 2011.
21. Rindskopf D, Rindskopf W. The value of latent class analysis in medical diagnosis. Stat Med. 1986;5(1):21-27.
22. Bandeen-Roche K, Miglioretti DL, Zeger SL, et al. Latent variable regression for multiple discrete outcomes. J Am Stat Assoc. 1997;92(440):1375- 1386.
23. Collins LM, Wugalter SE. Latent class models for stage-sequential dynamic latent variables. Multivariate Behav Res. 1992;27(1):131-157.
24. Reboussin BA, Reboussin DM, Liang K-Y, et al. Latent transition modeling of progression of health-risk behavior. Multivariate Behav Res. 1998;33(4):457-478.
25. Thylefors B, Dawson CR, Jones BR, et al. A simple system for the assessment of trachoma and its complications. Bull World Health Organ. 1987;65(4):477-483.
26. Blake IM, Burton MJ, Bailey RL, et al. Estimating household and community transmission of ocular Chlamydia trachomatis. PLoS Negl Trop Dis. 2009;3(3):e401.
27. Blake IM, Burton MJ, Solomon AW, et al. Targeting antibiotics to households for trachoma control. PLoS Negl Trop Dis. 2010;4(11):e862.
28. Burton MJ, Holland MJ, Faal N, et al. Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophthalmol Vis Sci. 2003;44(10):4215-4222.
29. Burton MJ, Holland MJ, Makalo P, et al. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet. 2005;365(9467):1321-1328.
30. Solomon AW, Holland MJ, Alexander ND, et al. Mass treatment with single-dose azithromycin for trachoma. N Engl J Med. 2004;351(19):1962-1971.
31. Solomon AW, Holland MJ, Burton MJ, et al. Strategies for control of trachoma: observational study with quantitative PCR. Lancet. 2003;362(9379):198-204.
32. Asparouhov T, Muthén BO. Multilevel mixture models. In: Hancock GR, Samuelson KM, eds. Advances in Latent Variable Mixture Models. Charlotte, NC: Information Age Publishing; 2008:27-51.
33. Muthén BO, Asparouhov T. Multilevel regression mixture analysis. J R Statist Soc A. 2009;172(3):639-657.
34. Van Horn ML, Fagan AA, Jaki T, et al. Using multilevel mixtures to evaluate intervention effects in group randomized trials. Multivariate Behav Res. 2008;43(2):289-326.
35. Henry KL, Muthén BO. Multilevel latent class analysis: an application of adolescent smoking typologies with individual and contextual predictors. Struct Equ Modeling. 2010;17(2): 193-215.
36. Vermunt JK. Multilevel latent class models. Sociol Methodol. 2003;33:213-239.
37. Vermunt JK. Latent class and finite mixture models for multilevel data sets. Stat Methods Med Res. 2008;17:33-51.
38. Muthén LK, Muthén BO. Mplus Statistical Analysis With Latent Variables User's Guide. Los Angeles, CA: Muthén & Muthén; 2010.
39. Keenan JD, Lakew T, Alemayehu W, et al. Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachoma. Am J Trop Med Hyg. 2010;82(3):482-487.
40. Yang JL, Schachter J, Moncada J, et al. Comparison of an rRNA-based and DNA-based nucleic acid amplification test for the detection of Chlamydia trachomatis in trachoma. Br J Ophthalmol. 2007;91(3):293-295.
41. Bird M, Dawson CR, Schachter JS, et al. Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas? J Infect Dis. 2003;187(10): 1669-1673.
42. Harding-Esch EM, Edwards T, Sillah A, et al. Active trachoma and ocular Chlamydia trachomatis infection in two Gambian regions: on course for elimination by 2020? PLoS Negl Trop Dis. 2009;3(12):e573.
43. Collins LM, Graham JW. The effect of the timing and spacing of observations in longitudinal studies of tobacco and other drug use: temporal design considerations. Drug Alcohol Depend. 2002;68(1 suppl):85S-96S.